REG - Burning Rock Biotech - Study results published in the Cancer Cell

Burning Rock BiotechAnnouncement

08/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230908:nRSH8039La&default-theme=true

RNS Number : 8039L  Burning Rock Biotech Limited  08 September 2023

Burning Rock's minimal residual disease (MRD) product supports advancement in
early-stage non-small cell lung cancer treatment, with results published in
the Cancer Cell

 

 

GUANGZHOU, China, September 7, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech
Limited (NASDAQ: BNR and LSE: BNR, the "Company" or "Burning Rock") is
delighted to announce that our personalized Minimal Residual Disease (MRD)
product, CanCatch(®) (PROPHET(TM) panel), was enrolled in a prospective
observational study (MEDAL, MEthylation based Dynamic Analysis for Lung
cancer, NCT03634826).

 

The MEDAL is a 5-year study that aimed to investigate the clinical utility of
MRD in patients with non-small cell lung cancer (NSCLC) with various
approaches to ctDNA detection, including MEDAL-Methylation and  MEDAL-PROPHET
(a novel Patient-specific pROgnostic and Potential tHErapeutic marker
Tracking). In MEDAL-PROPHET study, the CanCatch(®) demonstrated superior
performance in head-to-head comparisons with tumor-agnostic fixed-panel and
tumor-informed fixed-panel MRD assays.

 

We take pride in witnessing the CanCatch(®) as a sensitive tool to support
the clinical utility of ctDNA testing for MRD detection and recurrence
prediction in NSCLC, which identifies patients at high risk of relapse,
assists patients facing diagnostic challenges, and facilitates the
decision-making on later lines of treatment.

 

Reference

 1  Chen et al., Individualized tumor-informed circulating tumor DNA analysis
for postoperative monitoring of non-small cell lung cancer, Cancer Cell
(2023),  https://doi.org/10.1016/j.ccell.2023.08.010
(https://doi.org/10.1016/j.ccell.2023.08.010) .

 

 

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose mission is to
guard life via science, focuses on the application of next generation
sequencing (NGS) technology in the field of precision oncology. Its business
consists of i) NGS-based therapy selection testing for late-stage cancer
patients, and ii) cancer early detection, which has moved beyond
proof-of-concept R&D into the clinical validation stage.

 

For more information about Burning Rock, please visit: www.brbiotech.com.

 

Enquiries:

Contact: IR@brbiotech.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESNKFBNBBKKBCK